RSS-Feed abonnieren
DOI: 10.1055/s-0035-1571214
Botulinum Toxin Treatment of Autonomic Disorders: Focal Hyperhidrosis and Sialorrhea
Publikationsverlauf
Publikationsdatum:
11. Februar 2016 (online)
![](https://www.thieme-connect.de/media/sin/201601/lookinside/thumbnails/10-1055-s-0035-1571214_0075-1.jpg)
Abstract
Primary focal hyperhidrosis is a common autonomic disorder that significantly impacts quality of life. It is characterized by excessive sweating confined to circumscribed areas, such as the axillae, palms, soles, and face. Less frequent types of focal hyperhidrosis secondary to underlying causes include gustatory sweating in Frey's syndrome and compensatory sweating in Ross' syndrome and after sympathectomy. Approval of onabotulinumtoxinA for severe primary axillary hyperhidrosis in 2004 has revolutionized the treatment of this indication. Meanwhile further type A botulinum neurotoxins like abobotulinumtoxinA and incobotulinumtoxinA, as well as the type B botulinum neurotoxin rimabotulinumtoxinB are successfully used off-label for axillary and various other types of focal hyperhidrosis. For unexplained reasons, the duration of effect differs considerably at different sites. Beside hyperhidrosis, botulinum neurotoxin is also highly valued for the treatment of sialorrhea affecting patients with Parkinson's disease, cerebral palsy, amyotrophic lateral sclerosis, motor neuron disease, and other neurologic conditions. With correct dosing and application, side effects are manageable and transient.
-
References
- 1 Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol 2004; 51 (2) 241-248
- 2 Rosell K, Hymnelius K, Swartling C. Botulinum toxin type A and B improve quality of life in patients with axillary and palmar hyperhidrosis. Acta Derm Venereol 2013; 93 (3) 335-339
- 3 Kouris A, Armyra K, Christodoulou C, Karimali P, Karypidis D, Kontochristopoulos G. Quality of life in patients with focal hyperhidrosis before and after treatment with botulinum toxin A. ISRN Dermatol 2014; 2014: 308650
- 4 Hamm H. Impact of hyperhidrosis on quality of life and its assessment. Dermatol Clin 2014; 32 (4) 467-476
- 5 Hamm H, Naumann MK. Hyperhidrosis. In: Truong D, Hallett M, Zachary C, Dressler D, , eds. Handbook of Botulinum Toxin Therapy. 2nd ed. Cambridge: Cambridge University Press; 2013: 194-202
- 6 Stashak AB, Brewer JD. Management of hyperhidrosis. Clin Cosmet Investig Dermatol 2014; 7: 285-299
- 7 Lear W, Kessler E, Solish N, Glaser DA. An epidemiological study of hyperhidrosis. Dermatol Surg 2007; 33 (1 Spec No.): S69-S75
- 8 Lakraj AA, Moghimi N, Jabbari B. Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins (Basel) 2013; 5 (4) 821-840
- 9 Lee KY, Levell NJ. Turning the tide: a history and review of hyperhidrosis treatment. JRSM Open 2014; 5 (1) 2042533313505511
- 10 Wolosker N, de Campos JR, Kauffman P, Puech-Leão P. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg 2012; 55 (6) 1696-1700
- 11 Ibrahim O, Kakar R, Bolotin D , et al. The comparative effectiveness of suction-curettage and onabotulinumtoxin-A injections for the treatment of primary focal axillary hyperhidrosis: a randomized control trial. J Am Acad Dermatol 2013; 69 (1) 88-95
- 12 Hong HC, Lupin M, O'Shaughnessy KF. Clinical evaluation of a microwave device for treating axillary hyperhidrosis. Dermatol Surg 2012; 38 (5) 728-735
- 13 Lee SJ, Chang KY, Suh DH, Song KY, Ryu HJ. The efficacy of a microwave device for treating axillary hyperhidrosis and osmidrosis in Asians: a preliminary study. J Cosmet Laser Ther 2013; 15 (5) 255-259
- 14 Atkinson JL, Fode-Thomas NC, Fealey RD, Eisenach JH, Goerss SJ. Endoscopic transthoracic limited sympathotomy for palmar-plantar hyperhidrosis: outcomes and complications during a 10-year period. Mayo Clin Proc 2011; 86 (8) 721-729
- 15 Benson RA, Palin R, Holt PJ, Loftus IM. Diagnosis and management of hyperhidrosis. BMJ 2013; 347: f6800
- 16 Naumann M, Hofmann U, Bergmann I, Hamm H, Toyka KV, Reiners K. Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 1998; 134 (3) 301-304
- 17 Dressler D, Adib Saberi F. Towards a dose optimisation of botulinum toxin therapy for axillary hyperhidrosis: comparison of different Botox(®) doses. J Neural Transm (Vienna) 2013; 120 (11) 1565-1567
- 18 Baumann L, Slezinger A, Halem M , et al. Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis. Dermatol Surg 2005; 31 (3) 263-270
- 19 Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics 2014; 8: 227-241
- 20 Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm (Vienna) 2013; 120 (2) 275-290
- 21 Naumann M, Carruthers A, Carruthers J , et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord 2010; 25 (13) 2211-2218
- 22 Dressler D. Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system. J Neurol 2013; 260 (3) 701-713
- 23 Kouris A, Agiasofitou E, Gregoriou S, Sofouri E, Kontochristopoulos G, Panagopoulos G. Generalized neurological symptoms following treatment of focal hyperhidrosis with botulinum toxin A. Int J Dermatol 2014; 53 (11) e544-e547
- 24 Chiarello D, Piombo M, Corbetto M , et al. Relapsing-remitting severe generalized muscular weakness after botulinum toxin treatment for hyperhidrosis. Muscle Nerve 2014; 50 (3) 456-457
- 25 Ghasemi M, Norouzi R, Salari M, Asadi B. Iatrogenic botulism after the therapeutic use of botulinum toxin-A: a case report and review of the literature. Clin Neuropharmacol 2012; 35 (5) 254-257
- 26 Baumann LS, Halem ML. Systemic adverse effects after botulinum toxin type B (Myobloc) injections for the treatment of palmar hyperhidrosis. Arch Dermatol 2003; 139 (2) 226-227
- 27 Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ 2001; 323 (7313) 596-599
- 28 Dressler D, Adib Saberi F, Benecke R. Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 2002; 249 (12) 1729-1732
- 29 Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003; 49 (1) 34-38
- 30 Baumann L, Slezinger A, Halem M , et al. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis. Int J Dermatol 2005; 44 (5) 418-424
- 31 Karlqvist M, Rosell K, Rystedt A, Hymnelius K, Swartling C. Botulinum toxin B in the treatment of craniofacial hyperhidrosis. J Eur Acad Dermatol Venereol 2014; 28 (10) 1313-1317
- 32 Hosp C, Naumann MK, Hamm H. [Botulinum toxin in focal hyperhidrosis. An update]. Hautarzt 2012; 63 (6) 469-476
- 33 Tan M, Kim E, Koren G, Bozzo P. Botulinum toxin type A in pregnancy. Can Fam Physician 2013; 59 (11) 1183-1184
- 34 Heckmann M, Ceballos-Baumann AO, Plewig G ; Hyperhidrosis Study Group. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 2001; 344 (7) 488-493
- 35 Vadoud-Seyedi J, Simonart T. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study. Br J Dermatol 2007; 156 (5) 986-989
- 36 Talarico-Filho S, Mendonça DO Nascimento M, Sperandeo DE Macedo F, DE Sanctis Pecora C. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg 2007; 33 (1 Spec No.): S44-S50
- 37 Dressler D. Comparing Botox and Xeomin for axillar hyperhidrosis. J Neural Transm (Vienna) 2010; 117 (3) 317-319
- 38 Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY ; North American Botox in Primary Axillary Hyperhidrosis Clinical Study Group. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol 2007; 56 (4) 604-611
- 39 Naumann M, Dressler D, Hallett M , et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon 2013; 67: 141-152
- 40 Lowe N, Campanati A, Bodokh I , et al. The place of botulinum toxin type A in the treatment of focal hyperhidrosis. Br J Dermatol 2004; 151 (6) 1115-1122
- 41 Naumann M, Lowe NJ, Kumar CR, Hamm H ; Hyperhidrosis Clinical Investigators Group. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 2003; 139 (6) 731-736
- 42 Naumann MK, Hamm H, Lowe NJ ; Botox Hyperhidrosis Clinical Study Group. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol 2002; 147 (6) 1218-1226
- 43 Lowe PL, Cerdan-Sanz S, Lowe NJ. Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis: efficacy and duration with repeated treatments. Dermatol Surg 2003; 29 (5) 545-548
- 44 D'Epiro S, Macaluso L, Salvi M , et al. Safety and prolonged efficacy of botulin toxin A in primary hyperhidrosis. Clin Ter 2014; 165 (6) e395-e400
- 45 Lecouflet M, Leux C, Fenot M, Célerier P, Maillard H. Duration of efficacy increases with the repetition of botulinum toxin A injections in primary axillary hyperhidrosis: a study in 83 patients. J Am Acad Dermatol 2013; 69 (6) 960-964
- 46 Schnider P, Binder M, Auff E, Kittler H, Berger T, Wolff K. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol 1997; 136 (4) 548-552
- 47 Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Iyer S. Efficacy and safety of botulinum toxin type A in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg 2002; 28 (9) 822-827
- 48 Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 2003; 149 (5) 1041-1045
- 49 Saadia D, Voustianiouk A, Wang AK, Kaufmann H. Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology 2001; 57 (11) 2095-2099
- 50 Shelley WB, Talanin NY, Shelley ED. Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol 1998; 38 (2 Pt 1): 227-229
- 51 Solomon BA, Hayman R. Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol 2000; 42 (6) 1026-1029
- 52 Naver H, Swartling C, Aquilonius SM. Palmar and axillary hyperhidrosis treated with botulinum toxin: one-year clinical follow-up. Eur J Neurol 2000; 7 (1) 55-62
- 53 Ito K, Yanagishita T, Ohshima Y, Tamada Y, Watanabe D. Therapeutic effectiveness of botulinum toxin type A based on severity of palmar hyperhidrosis. J Dermatol 2011; 38 (9) 859-863
- 54 El Kahky HM, Diab HM, Aly DG, Farag NM. Efficacy of onabotulinum toxin A (Botox) versus abobotulinum toxin A (Dysport) using a conversion factor (1 : 2.5) in treatment of primary palmar hyperhidrosis. Dermatol Res Pract 2013; 2013: 686329
- 55 Kinkelin I, Hund M, Naumann M, Hamm H. Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol 2000; 143 (4) 824-827
- 56 Doft MA, Hardy KL, Ascherman JA. Treatment of hyperhidrosis with botulinum toxin. Aesthet Surg J 2012; 32 (2) 238-244
- 57 Lowe PL, Lowe NJ. Botulinum toxin type B: pH change reduces injection pain, retains efficacy. Dermatol Surg 2014; 40 (12) 1328-1333
- 58 Campanati A, Giuliodori K, Martina E, Giuliano A, Ganzetti G, Offidani A. Onabotulinumtoxin type A (Botox(®)) versus incobotulinumtoxin type A (Xeomin(®)) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial. J Neural Transm (Vienna) 2014; 121 (1) 21-26
- 59 Basciani M, Di Rienzo F, Bizzarrini M, Zanchi M, Copetti M, Intiso D. Efficacy of botulinum toxin type B for the treatment of primary palmar hyperhidrosis: a prospective, open, single-blind, multi-centre study. Arch Dermatol Res 2014; 306 (5) 497-503
- 60 Campanati A, Lagalla G, Penna L, Gesuita R, Offidani A. Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements. J Am Acad Dermatol 2004; 51 (3) 345-348
- 61 Paracka L, Kollewe K, Dengler R, Dressler D. Botulinum toxin therapy for hyperhidrosis: reduction of injection site pain by nitrous oxide/oxygen mixtures. J Neural Transm (Vienna) 2015; 122 (9) 1279-1282
- 62 Li M, Goldberger BA, Hopkins C. Fatal case of BOTOX-related anaphylaxis?. J Forensic Sci 2005; 50 (1) 169-172
- 63 Campanati A, Bernardini ML, Gesuita R, Offidani A. Plantar focal idiopathic hyperhidrosis and botulinum toxin: a pilot study. Eur J Dermatol 2007; 17 (1) 52-54
- 64 Vadoud-Seyedi J. Treatment of plantar hyperhidrosis with botulinum toxin type A. Int J Dermatol 2004; 43 (12) 969-971
- 65 Glaser DA, Hebert AA, Pariser DM, Solish N. Palmar and plantar hyperhidrosis: best practice recommendations and special considerations. Cutis 2007; 79 (5, Suppl) 18-28
- 66 Benohanian A. Treatment of recalcitrant plantar hyperhidrosis with type-A botulinum toxin injections and aluminum chloride in salicylic acid gel. Dermatol Online J 2008; 14 (2) 5
- 67 Anders D, Moosbauer S, Naumann MK, Hamm H. Craniofacial hyperhidrosis successfully treated with botulinum toxin type A. Eur J Dermatol 2008; 18 (1) 87-88
- 68 Trindade de Almeida AR, Marques E, de Almeida J, Cunha T, Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007; 33 (1 Spec No.): S37-S43
- 69 Naumann M, Zellner M, Toyka KV, Reiners K. Treatment of gustatory sweating with botulinum toxin. Ann Neurol 1997; 42 (6) 973-975
- 70 Eckardt A, Kuettner C. Treatment of gustatory sweating (Frey's syndrome) with botulinum toxin A. Head Neck 2003; 25 (8) 624-628
- 71 Guntinas-Lichius O. Increased botulinum toxin type A dosage is more effective in patients with Frey's syndrome. Laryngoscope 2002; 112 (4) 746-749
- 72 Ng S, Torjek C, Hovan A. Management of Frey syndrome using botulinum neurotoxin: a case report. J Can Dent Assoc 2009; 75 (9) 651-654
- 73 Kreyden OP, Scheidegger EP. Anatomy of the sweat glands, pharmacology of botulinum toxin, and distinctive syndromes associated with hyperhidrosis. Clin Dermatol 2004; 22 (1) 40-44
- 74 Martos Díaz P, Bances del Castillo R, Mancha de la Plata M , et al. Clinical results in the management of Frey's syndrome with injections of Botulinum toxin. Med Oral Patol Oral Cir Bucal 2008; 13 (4) E248-E252
- 75 de Bree R, Duyndam JE, Kuik DJ, Leemans CR. Repeated botulinum toxin type A injections to treat patients with Frey syndrome. Arch Otolaryngol Head Neck Surg 2009; 135 (3) 287-290
- 76 Cantarella G, Berlusconi A, Mele V, Cogiamanian F, Barbieri S. Treatment of Frey's syndrome with botulinum toxin type B. Otolaryngol Head Neck Surg 2010; 143 (2) 214-218
- 77 Bergmann I, Dauphin M, Naumann M , et al. Selective degeneration of sudomotor fibers in Ross syndrome and successful treatment of compensatory hyperhidrosis with botulinum toxin. Muscle Nerve 1998; 21 (12) 1790-1793
- 78 Crowner BE, Torres-Russotto D, Carter AR, Racette BA. Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literature. Clin Neuropharmacol 2010; 33 (5) 243-247
- 79 Licht PB, Pilegaard HK. Severity of compensatory sweating after thoracoscopic sympathectomy. Ann Thorac Surg 2004; 78 (2) 427-431
- 80 Bechara FG, Sand M, Moussa G , et al. Treatment of unilateral compensatory sweating after endoscopical thoracic sympathectomy for general hyperhidrosis with botulinum toxin A. Dermatol Surg 2006; 32 (5) 745-748
- 81 Kim WO, Kil HK, Yoon KB, Noh KU. Botulinum toxin: a treatment for compensatory hyperhidrosis in the trunk. Dermatol Surg 2009; 35 (5) 833-838 , discussion 838
- 82 Hexsel D, Soirefmann M, Porto MD, Schilling-Souza J, Siega C. Fields of anhidrotic effects of abobotulinumtoxinA in patients with compensatory hyperhidrosis. Dermatol Surg 2015; 41 (Suppl. 01) S93-S100
- 83 Bechara FG, Sand M, Achenbach RK, Sand D, Altmeyer P, Hoffmann K. Focal hyperhidrosis of the anal fold: successful treatment with botulinum toxin A. Dermatol Surg 2007; 33 (8) 924-927
- 84 Charrow A, DiFazio M, Foster L, Pasquina PF, Tsao JW. Intradermal botulinum toxin type A injection effectively reduces residual limb hyperhidrosis in amputees: a case series. Arch Phys Med Rehabil 2008; 89 (7) 1407-1409
- 85 Kern U, Kohl M, Seifert U, Schlereth T. Botulinum toxin type B in the treatment of residual limb hyperhidrosis for lower limb amputees: a pilot study. Am J Phys Med Rehabil 2011; 90 (4) 321-329
- 86 Hexsel DM, Dal'forno T, Hexsel CL. Inguinal, or Hexsel's hyperhidrosis. Clin Dermatol 2004; 22 (1) 53-59
- 87 Benson J, Daugherty KK. Botulinum toxin A in the treatment of sialorrhea. Ann Pharmacother 2007; 41 (1) 79-85
- 88 Giess R, Werner E, Beck M, Reiners C, Toyka KV, Naumann M. Impaired salivary gland function reveals autonomic dysfunction in amyotrophic lateral sclerosis. J Neurol 2002; 249 (9) 1246-1249
- 89 Truong DD, Bhidayasiri R. Evidence for the effectiveness of botulinum toxin for sialorrhoea. J Neural Transm (Vienna) 2008; 115 (4) 631-635
- 90 Naumann M, So Y, Argoff CE , et al; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70 (19) 1707-1714
- 91 Ellies M, Laskawi R, Tormählen G, Götz W. The effect of local injection of botulinum toxin A on the parotid gland of the rat: an immunohistochemical and morphometric study. J Oral Maxillofac Surg 2000; 58 (11) 1251-1256
- 92 Jackson CE, Gronseth G, Rosenfeld J , et al; Muscle Study Group. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009; 39 (2) 137-143
- 93 Guidubaldi A, Fasano A, Ialongo T , et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Mov Disord 2011; 26 (2) 313-319
- 94 Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006; 21 (5) 704-707
- 95 Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003; 61 (9) 1279-1281
- 96 Mancini F, Zangaglia R, Cristina S , et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003; 18 (6) 685-688
- 97 Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004; 62 (1) 37-40
- 98 Wilken B, Aslami B, Backes H. Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B. Neuropediatrics 2008; 39 (4) 200-204
- 99 Chan KH, Liang C, Wilson P, Higgins D, Allen GC. Long-term safety and efficacy data on botulinum toxin type A: an injection for sialorrhea. JAMA Otolaryngol Head Neck Surg 2013; 139 (2) 134-138
- 100 Anagnostou E, Rentzos M, Alexakis T, Zouvelou V, Zambelis T, Evdokimidis I. Volume matters: the influence of different botulinum toxin-A dilutions for sialorrhea in amyotrophic lateral sclerosis. Muscle Nerve 2013; 47 (2) 276-278